The clinical significance of detection of residual disease in childhood ALL.

[1]  C. E. van der Schoot,et al.  Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. , 1995, Leukemia.

[2]  E J Freireich,et al.  Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. , 1987, Science.

[3]  K. Foon,et al.  Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias , 2012, Cancer Treatment and Research.

[4]  J. Dongen,et al.  Terminal deoxynucleotidyl transferase (TdT)-positive cells in cerebrospinal fluid and development of overt CNS leukemia: a 5-year follow-up study in 113 children with a TdT-positive leukemia or non-Hodgkin's lymphoma. , 1989, Blood.

[5]  G. Tricot,et al.  Interphase in situ hybridization reveals minimal residual disease in early remission and return of the diagnostic clone in karyotypically normal relapse of acute lymphoblastic leukemia. , 1993, Leukemia.

[6]  J. V. van Dongen,et al.  Analysis of immunoglobulin and T cell receptor genes. Part I: Basic and technical aspects. , 1991, Clinica chimica acta; international journal of clinical chemistry.

[7]  C. Pui,et al.  Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and X. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Janossy,et al.  Cellular phenotypes of normal and leukemic hemopoietic cells determined by analysis with selected antibody combinations. , 1980, Blood.

[9]  S. Knuutila,et al.  Metaphase fluorescence in situ hybridization (FISH) in the follow‐up of 60 patients with haemkopietic malignancies , 1994, British journal of haematology.

[10]  A. Hoffbrand,et al.  Detection of minimal residual disease in ALL. , 1993, Cancer treatment and research.

[11]  E. Southern.  Detection of specific sequences among DNA fragments separated by gel electrophoresis. , 1975, Journal of molecular biology.

[12]  K. Bradstock,et al.  Interaction of acute leukemia cells with the bone marrow microenvironment: implications for control of minimal residual disease. , 1995, Leukemia & lymphoma.

[13]  C. Bartram,et al.  Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor delta chain sequences. , 1989, Blood.

[14]  P. Martiat,et al.  Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IgH probes and the polymerase chain reaction. , 1993, Blood.

[15]  A. Carroll,et al.  The tal gene undergoes chromosome translocation in T cell leukemia and potentially encodes a helix‐loop‐helix protein. , 1990, The EMBO journal.

[16]  A. Morley,et al.  Development of a highly sensitive assay, based on the polymerase chain reaction, for rare B‐lymphocyte clones in a polyclonal population , 1990, British Journal of Haematology.

[17]  J. V. van Dongen,et al.  Analysis of immunoglobulin and T cell receptor genes. Part II: Possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. , 1991, Clinica chimica acta; international journal of clinical chemistry.

[18]  M. L. Beau,et al.  Direct correlation of cytogenetic findings with cell morphology using in situ hybridization: an analysis of suspicious cells in bone marrow specimens of two patients completing therapy for acute lymphoblastic leukemia. , 1991 .

[19]  C. Berard,et al.  Presence of clonal chromosome abnormalities in virtually all cases of acute lymphoblastic leukemia. , 1985, The New England journal of medicine.

[20]  Y. Kurosawa,et al.  Organization of human immunoglobulin heavy chain diversity gene loci. , 1988, The EMBO journal.

[21]  S. Lawler,et al.  Prognostic implications of chromosomal findings in acute lymphoblastic leukaemia at diagnosis. , 1978, British medical journal.

[22]  J. V. van Dongen,et al.  Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. , 1992, Leukemia.

[23]  R. Gale,et al.  Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia , 1991, The Lancet.

[24]  L. Foroni,et al.  1 Genetic changes: Relevance for diagnosis and detection of minimal residual disease in acute lymphoblastic leukaemia , 1994 .

[25]  M. Slovak,et al.  Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia. , 1995, Blood.

[26]  M. Wysocki,et al.  Late relapse after presumed cure of childhood acute lymphoblastic leukemia. , 1993, Acta haematologica Polonica.

[27]  J. Rowley,et al.  Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. , 1993, Blood.

[28]  C. Bloomfield,et al.  Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[30]  M R Loken,et al.  Five-dimensional flow cytometry as a new approach for blood and bone marrow differentials. , 1988, Cytometry.

[31]  P. Marynen,et al.  The 12;21 translocation involving TEL and deletion of the other TEL allele: two frequently associated alterations found in childhood acute lymphoblastic leukemia. , 1996, Blood.

[32]  H. Cavé,et al.  Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. , 1994, Blood.

[33]  P. Neame,et al.  Monoclonal antibodies in the management of acute leukemia , 1995, American journal of hematology.

[34]  Y. C. Chen,et al.  Lymphoblast colony-culture assay in acute lymphoblastic leukemia: a quantitative approach. , 1993, Leukemia research.

[35]  A. Abbas,et al.  Cellular and Molecular Immunology , 1991 .

[36]  J. Wiegant,et al.  Detection of the Philadelphia chromosome in interphase nuclei. , 1990, Cytogenetics and cell genetics.

[37]  S. Smith,et al.  Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. Oakhill,et al.  The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia , 1993, British journal of haematology.

[39]  B. Strauss.  The origin of point mutations in human tumor cells. , 1992, Cancer research.

[40]  A. Hagenbeek,et al.  Bivariate flow karyotyping in human Philadelphia-positive chronic myelocytic leukemia , 1988 .

[41]  C. Bartram.  Detection of minimal residual leukemia by the polymerase chain reaction: potential implications for therapy. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[42]  N. Goulden,et al.  PCR assessment of bone marrow status in ‘isolated’extramedullary relapse of childhood B‐precursor acute lymphoblastic leukaemia , 1994, British journal of haematology.

[43]  P. N. Rao,et al.  Mammalian Cell Fusion : Induction of Premature Chromosome Condensation in Interphase Nuclei , 1970, Nature.

[44]  S. Korsmeyer,et al.  Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[45]  P. Rabinovitch,et al.  Simultaneous cell cycle analysis and two-color surface immunofluorescence using 7-amino-actinomycin D and single laser excitation: applications to study of cell activation and the cell cycle of murine Ly-1 B cells. , 1986, Journal of immunology.

[46]  G. Wang,et al.  Expression of AML1-ETO fusion transcripts and detection of minimal residual disease in t(8;21)-positive acute myeloid leukemia. , 1993, Oncogene.

[47]  J. V. van Dongen,et al.  Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: an updated meeting report and review. , 1993, Leukemia.

[48]  Hall,et al.  Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA , 1997, British journal of haematology.

[49]  R. Herrmann,et al.  Correlation of bone marrow minimal residual disease and apparent isolated extramedullary relapse in childhood acute lymphoblastic leukaemia. , 1995, Leukemia.

[50]  F. Uckun,et al.  Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. , 1993, The New England journal of medicine.

[51]  J. Sklar,et al.  Continuing rearrangement but absence of somatic hypermutation in immunoglobulin genes of human B cell precursor leukemia , 1988, The Journal of experimental medicine.

[52]  G. Reaman,et al.  Late soft tissue recurrence of acute lymphoblastic leukemia in a site of antecedent trauma. , 1978, The Journal of pediatrics.

[53]  B. Lange,et al.  Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment. , 1990, The New England journal of medicine.

[54]  Z Chen,et al.  Application of fluorescence in situ hybridization in hematological disorders. , 1992, Cancer genetics and cytogenetics.

[55]  P. Hérait,et al.  Very late recurrence of childhood acute lymphoblastic leukemia treated with chemoimmunotherapy: a report of three cases occurring 19, 11, and 9 years after discontinuation of chemotherapy. , 1989, Medical and pediatric oncology.

[56]  Y. Kaneko,et al.  Flow cytometric evidence for minimal residual disease and cytological heterogeneities in acute lymphoblastic leukemia with severe hypodiploidy , 1989, American journal of hematology.

[57]  S. Richards,et al.  Long survival in childhood lymphoblastic leukaemia. , 1987, British Journal of Cancer.

[58]  M. Palmer,et al.  Routine bone marrow examination in the management of acute lymphoblastic leukaemia of childhood. , 1981, Journal of clinical pathology.

[59]  F. Lo Coco,et al.  Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL‐1/AF‐4 positive‐acute lymphoblastic leukaemia , 1996, British journal of haematology.

[60]  S. Piantadosi,et al.  Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. , 1991, Blood.

[61]  A. Hagemeijer,et al.  TdT positive B‐cell acute lymphoblastic leukaemia (B‐ALL) without Burkitt characteristics , 1988, British journal of haematology.

[62]  M. Potter,et al.  A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor delta gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. , 1994, Blood.

[63]  H. Kantarjian,et al.  Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myeloid leukemia. , 1987, Blood.

[64]  M. Greaves.  Silence of the leukemic clone. , 1997, The New England journal of medicine.

[65]  K. Mullis,et al.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. , 1985, Science.

[66]  G. Birnie,et al.  Sequestration of Philadelphia chromosome-positive cells in the bone marrow of a chronic myeloid leukemia patient in very prolonged remission. , 1990, Leukemia.

[67]  J. V. van Dongen,et al.  Immunophenotypic and immunogenotypic detection of minimal residual disease in acute lymphoblastic leukemia. , 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[68]  M. Greaves,et al.  Acute lymphoblastic leukaemia associated antigen. IV. Expression on non-leukaemic 'lymphoid' cells. , 1980, Leukemia research.

[69]  Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia. , 1986 .

[70]  R. Kitchens,et al.  Phenotypic heterogeneity of TDT+ cells in the blood and bone marrow: implications for surveillance of residual leukemia. , 1989, Blood.

[71]  R. Noble,et al.  A classification of transplantable tumors in Nb rats controlled by estrogen from dormancy to autonomy. , 1975, Cancer research.

[72]  G. Gaidano,et al.  Persistence of E2A/PBX1 transcripts in t(1;19) childhood acute lymphoblastic leukemia: correlation with chemotherapy intensity and clinical outcome. , 1996, Leukemia research.

[73]  Z. Estrov,et al.  Growth requirements for human acute lymphoblastic leukemia cells: refinement of a clonogenic assay. , 1988, Cancer research.

[74]  M. Haber,et al.  Detection of evolving immunoglobulin heavy-chain gene rearrangements in acute lymphoblastic leukemia: a PCR-based assay employing overlapping DJH primers. , 1995, Leukemia.

[75]  B. Ness,et al.  Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease. , 1991, Blood.

[76]  B. Barlogie,et al.  Flow cytometry in clinical cancer research. , 1983, Cancer research.

[77]  R. Scheuermann,et al.  Cancer dormancy: Opportunities for new therapeutic approaches , 1997, Nature Medicine.

[78]  C. Pui,et al.  Lineage switch in acute leukemia. , 1984, Blood.

[79]  G. Avvisati,et al.  Combined cytogenetic, FISH and molecular analysis in acute promyelocytic leukaemia at diagnosis and in complete remission , 1995, British journal of haematology.

[80]  G. Basso,et al.  Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. , 1992, Leukemia.

[81]  D. Johnston,et al.  Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. , 1997, The New England journal of medicine.

[82]  H. Kantarjian,et al.  Acute lymphoblastic leukemia a comprehensive review with emphasis on biology and therapy , 1995, Cancer.

[83]  D. Fischer,et al.  Frequency of bone marrow aspirates to monitor acute lymphoblastic leukemia in childhood. , 1983, The Journal of pediatrics.

[84]  F. Behm,et al.  The definition of remission in acute leukemia with immunologic techniques. , 1991, Bone marrow transplantation.

[85]  P. Martiat,et al.  False-positive results with PCR to detect leukaemia-specific transcript , 1990, The Lancet.

[86]  J. Goldman,et al.  Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. , 1993 .

[87]  M. Bakkus,et al.  Detection of minimal residual disease in multiple myeloma and acute leukaemia , 1996, Medical oncology.

[88]  H. A. Erlich,et al.  Specific DNA amplification , 1988, Nature.

[89]  P. Martiat,et al.  Follow‐up of residual disease (MRD) in B lineage acute leukaemias using a simplified PCR strategy: evolution of MRD rather than its detection is correlated with clinical outcome , 1991, British journal of haematology.

[90]  J. Fry,et al.  DNase I treatment of Taq DNA polymerase for complete PCR decontamination. , 1992, BioTechniques.

[91]  J. V. van Dongen,et al.  Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. , 1994, Blood.

[92]  R. Higuchi,et al.  Simple and Rapid Preparation of Samples for PCR , 1989 .

[93]  R. Hast,et al.  Fluorescence in situ hybridization in combination with morphology detects minimal residual disease in remission and heralds relapse in acute leukaemia , 1996, British journal of haematology.

[94]  B. Lange,et al.  Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  K. McCredie,et al.  Predicting relapse of human leukemia by means of premature chromosome condensation. , 1980, The New England journal of medicine.

[96]  D. Campana.  Applications of cytometry to study acute leukemia: in vitro determination of drug sensitivity and detection of minimal residual disease. , 1994, Cytometry.

[97]  Z. Estrov,et al.  Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia. , 1994, Leukemia.

[98]  M. Potter,et al.  Transient erythroblastopenia of childhood with CD10, TdT, and cytoplasmic mu lymphocyte positivity in bone marrow. , 1990, Journal of clinical pathology.

[99]  B. Vogelstein,et al.  Immunoglobulin gene rearrangements in remission bone marrow specimens from patients with acute lymphoblastic leukemia. , 1986, Blood.

[100]  H. Sather,et al.  YIELD OF UNPREDICTED BONE-MARROW RELAPSE DIAGNOSED BY ROUTINE MARROW ASPIRATION IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKAEMIA A Report from the Children's Cancer Study Group , 1984, The Lancet.

[101]  D. Campana,et al.  Autologous bone marrow transplantation in acute lymphoblastic leukemia--preclinical immunologic studies. , 1988, Leukemia.

[102]  I. Penn.  Cancers complicating organ transplantation. , 1990, The New England journal of medicine.

[103]  D. Campana,et al.  The cytoplasmic expression of CD3 antigens in normal and malignant cells of the T lymphoid lineage. , 1987, Journal of immunology.

[104]  M. Cleary,et al.  The t(1;19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias. , 1991, Blood.

[105]  G. Huez,et al.  Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. , 1995, Blood.

[106]  L. Ball,et al.  The use of DNA probes to monitor minimal residual disease in childhood acute lymphoblastic leukaemia , 1989, British journal of haematology.

[107]  W. Kuo,et al.  Molecular cytometry applied to detection and characterization of disease-linked chromosome aberrations. , 1991, Bailliere's clinical haematology.

[108]  J. V. van Dongen,et al.  Southern blot patterns, frequencies, and junctional diversity of T-cell receptor-delta gene rearrangements in acute lymphoblastic leukemia. , 1993, Blood.

[109]  A. Hagenbeek,et al.  Nonhomogeneous distribution of leukemia in the bone marrow during minimal residual disease. , 1987, Blood.

[110]  M. Cooper,et al.  Pre-B-cell leukemia. A new phenotype of childhood lymphoblastic leukemia. , 1978, The New England journal of medicine.

[111]  S. Steinberg,et al.  Characterization of immunoglobulin and T-cell receptor gene patterns in B-cell precursor acute lymphoblastic leukemia of childhood. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  C. Civin,et al.  Flow cytometric detection of rare normal human marrow cells with immunophenotypes characteristic of acute lymphoblastic leukemia cells. , 1992, Leukemia.

[113]  G. Jackson,et al.  Relapse of acute lymphoblastic leukaemia 14 years after presentation: use of molecular techniques to confirm true re‐emergence , 1994, British journal of haematology.

[114]  C. Pui,et al.  Molecular evidence for minimal residual bone marrow disease in children with 'isolated' extra-medullary relapse of T-cell acute lymphoblastic leukemia. , 1994, Leukemia.

[115]  Z. Estrov,et al.  DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia , 1998, Leukemia.

[116]  A. Borkhardt,et al.  Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction. , 1995, Leukemia & lymphoma.

[117]  D Pinkel,et al.  Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization , 1990, Science.

[118]  B. Trask,et al.  Analytical approaches to detection and characterization of disease-linked chromosome aberrations. , 1990, Bone marrow transplantation.

[119]  K. Mullis,et al.  Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. , 1988, Science.

[120]  G. Sarkar,et al.  Shedding light on PCR contamination , 1990, Nature.

[121]  I. Magrath,et al.  Localization of breakpoints by polymerase chain reactions in burkitt's lymphoma with 8;14 translocations , 1990 .

[122]  J. D. Dickerman,et al.  Immunophenotypic characteristics of cerebrospinal fluid cells in children with acute lymphoblastic leukemia at diagnosis. , 1990, Blood.

[123]  M. Hancock,et al.  Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. , 1993, The New England journal of medicine.

[124]  S. Knuutila,et al.  Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia: a metaphase‐FISH study , 1996, British journal of haematology.

[125]  A. Kasprzyk,et al.  Increased sensitivity of minimal residual disease detection by interphase FISH in acute lymphoblastic leukemia with hyperdiploidy , 1997, Leukemia.

[126]  A. Morley,et al.  Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction , 1994, The Lancet.

[127]  G. Janossy,et al.  Diagnosis of meningeal involvement in patients with acute lymphoblastic leukemia: Immunofluorescence for terminal transferase , 1981, Cancer.

[128]  C. Anderson,et al.  Human leukocyte IgG Fc receptors. , 1986, Immunology today.

[129]  W. Huang,et al.  Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers. , 1996, Cancer genetics and cytogenetics.

[130]  A. Bernard,et al.  Changes in surface antigens on malignant T cells from lymphoblastic lymphomas at relapse: an appraisal with monoclonal antibodies and microfluorometry. , 1982, Blood.

[131]  M. Koehler,et al.  Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. , 1991, Blood.

[132]  P. Hokland,et al.  Differences in relative DNA content between human peripheral blood and bone marrow subpopulations--consequences for DNA index calculations. , 1993, Cytometry.

[133]  D. Pinkel,et al.  Fluorescence in situ hybridization with human chromosome-specific libraries: detection of trisomy 21 and translocations of chromosome 4. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[134]  A. Biondi,et al.  Reverse transcriptase/polymerase chain reaction follow‐up and minimal residual disease detection in t(1;19)‐positive acute lymphoblastic leukaemia , 1996, British journal of haematology.

[135]  T. Barbui,et al.  Minimal residual disease in acute lymphoblastic leukemia detected by immune selection and gene rearrangement analysis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[136]  E. Bryant,et al.  Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia. , 1991, Blood.

[137]  J. Crolla,et al.  Detection of minimal residual disease in childhood acute lymphoblastic leukaemia using fluorescence in‐situ hybridization , 1995, British journal of haematology.

[138]  J. V. van Dongen,et al.  Detection of residual disease in acute leukemia using immunological markers. , 1988, Cancer treatment and research.

[139]  D. Campana,et al.  Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. , 1995, Blood.

[140]  B. Hall,et al.  Adaptive mutations in Escherichia coli as a model for the multiple mutational origins of tumors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[141]  M. Greaves.  Differentiation-linked leukemogenesis in lymphocytes. , 1986, Science.

[142]  E. Estey,et al.  Expression of unusual immunophenotype combinations in acute myelogenous leukemia. , 1993, Blood.

[143]  D. Campana,et al.  The immunologic detection of minimal residual disease in acute leukemia. , 1990, Blood.

[144]  J. Silber,et al.  Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  Y. Ito,et al.  Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: is molecular remission a milestone for achieving a cure? , 1994, Leukemia & lymphoma.

[146]  B. Lange,et al.  Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[147]  M. Cleary,et al.  PBX2 and PBX3, new homeobox genes with extensive homology to the human proto-oncogene PBX1 , 1991, Molecular and cellular biology.

[148]  J Anastasi,et al.  Detection of numerical chromosomal abnormalities in neoplastic hematopoietic cells by in situ hybridization with a chromosome-specific probe. , 1990, The American journal of pathology.

[149]  H. Gross,et al.  Detection of rare cells at a frequency of one per million by flow cytometry. , 1993, Cytometry.

[150]  Henry A. Erlich,et al.  PCR Technology: Principles and Applications for DNA Amplification , 1989 .

[151]  G. Wilson,et al.  Clonal stability in late‐relapsing childhood lymphoblastic leukaemia , 1997, British journal of haematology.

[152]  G. Rovera,et al.  Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. , 1997, Blood.

[153]  P. Sirigu,et al.  Histochemical demonstration of acetylcholinesterase activity in human Meibomian glands. , 1996, European journal of histochemistry : EJH.

[154]  H. Kantarjian,et al.  Molecular Genetics and Therapy of Leukemia , 1996, Cancer Treatment and Research.

[155]  L. Foroni,et al.  Minimal residual disease in acute lymphoblastic leukaemia--PCR analysis of immunoglobulin gene rearrangements. , 1993, Leukemia & lymphoma.

[156]  R. Nowak,et al.  Detection of aneuploid cells in acute lymphoblastic leukemia with flow cytometry before and after therapy. , 1994, Leukemia research.

[157]  Z. Estrov,et al.  Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. , 1986, The New England journal of medicine.

[158]  B. Schlegelberger,et al.  Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumor cells. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[159]  N. Arnheim,et al.  The polymerase chain reaction. , 1989, Trends in genetics : TIG.

[160]  S. Heimfeld,et al.  Use of fluorescence threshold triggering and high-speed flow cytometry for rare event detection. , 1995, Cytometry.

[161]  F. Galibert,et al.  In vitro amplification of T cell gamma gene rearrangements: a new tool for the assessment of minimal residual disease in acute lymphoblastic leukemias. , 1989, Leukemia.

[162]  D. Johnston,et al.  Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. , 1995, Leukemia.

[163]  H. Kantarjian,et al.  Usefulness of detection of minimal residual disease by ‘hypermetaphase’ fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia , 1997, Bone Marrow Transplantation.

[164]  Z. Estrov,et al.  The clinical significance of residual disease in childhood acute lymphoblastic leukemia as detected by polymerase chain reaction amplification by antigen-receptor gene sequences. , 1996, Leukemia & lymphoma.

[165]  R. Warnke,et al.  Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[166]  S. Tonegawa.  Somatic generation of antibody diversity , 1983, Nature.

[167]  R. Kurzrock,et al.  Molecular Biology in Cancer Medicine , 1999 .

[168]  U. Surti,et al.  Content and organization of the human Ig VH locus: definition of three new VH families and linkage to the Ig CH locus. , 1988, The EMBO journal.

[169]  J. Tanzer,et al.  Quantitative determination of the hybrid Bcr‐Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy , 1992, British journal of haematology.

[170]  U. Kees,et al.  Late leukemic relapse 10 years from diagnosis in a child on recombinant human growth hormone. , 1993, Pediatric hematology and oncology.

[171]  M. Taniwaki,et al.  Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. , 1996, Leukemia.

[172]  S. Raimondi.  Current Status of Cytogenetic Research in Childhood Acute Lymphoblastic Leukemia , 1993 .

[173]  O. J. Johansen,et al.  Late relapses after treatment for acute lymphoblastic leukemia in childhood: a population-based study from the Nordic countries. , 1989, Medical and pediatric oncology.

[174]  A. Hagenbeek,et al.  Minimal Residual Disease in Acute Leukemia , 1984, Developments in Oncology.

[175]  R. Webster,et al.  Immunologic rebound after cessation of long-term chemotherapy in acute leukemia. , 1972, Blood.

[176]  J. Sklar.  Polymerase chain reaction: the molecular microscope of residual disease. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[177]  G. Kitchingman.  Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia. , 1994, Leukemia.

[178]  R. Foà,et al.  High prevalence of T-cell receptor V delta 2-(D)-D delta 3 or D delta 1/2-D delta 3 rearrangements in B-precursor acute lymphoblastic leukemias. , 1990, Blood.

[179]  E. Thiel,et al.  Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction , 1991, The Lancet.

[180]  J. V. van Dongen,et al.  Differences in immunoglobulin heavy chain gene rearrangmeent patterns between bone marrow and blood samples in childhood precursor B-acute lymphoblastic leaukemia at diagnosis. , 1993, Leukemia.

[181]  D. Pinkel.  Lessons from 20 years of curative therapy of childhood acute leukaemia. , 1992, British Journal of Cancer.

[182]  C. Bartram,et al.  Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. , 1991, Blood.

[183]  Z. Estrov,et al.  Detection of minimal residual disease in all: biology, methods, and applications. , 1996, Cancer treatment and research.

[184]  A Krishan,et al.  Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining , 1975, The Journal of cell biology.

[185]  A. Keating,et al.  Acute leukemia occurring 19 years after treatment of acute lymphoblastic leukemia , 1987, Cancer.

[186]  Ó. Jónsson,et al.  Detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin hypervariable region specific oligonucleotide probes. , 1990, Blood.

[187]  S. George,et al.  Cytogenetic studies and their clinical correlates in adults with acute leukemia. , 1971, Annals of internal medicine.

[188]  D. Campana,et al.  The detection of residual acute lymphoblastic leukemia cells with immunologic methods and polymerase chain reaction: a comparative study. , 1990, Leukemia.

[189]  G. Janossy,et al.  Distribution of t lymphocyte subsets in the human bone marrow and thymus: an analysis with monoclonal antibodies. , 1981, Journal of immunology.

[190]  A. Hagemeijer,et al.  Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin. , 1991, Leukemia.